Insider Transactions in Q4 2021 at C4 Therapeutics, Inc. (CCCC)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 22
2021
|
Adam Crystal Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+25.0%
|
$30,000
$6.49 P/Share
|
|
Dec 17
2021
|
Malcolm Salter Director |
SELL
Open market or private sale
|
Direct |
755
-6.45%
|
$22,650
$30.25 P/Share
|
|
Dec 08
2021
|
Stewart Fisher Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,562
+12.95%
|
$61,686
$3.6 P/Share
|
|
Nov 19
2021
|
Malcolm Salter Director |
SELL
Open market or private sale
|
Direct |
755
-6.06%
|
$30,200
$40.11 P/Share
|
|
Oct 15
2021
|
Malcolm Salter Director |
SELL
Open market or private sale
|
Direct |
755
-5.71%
|
$33,220
$44.94 P/Share
|
|
Oct 08
2021
|
Adam Crystal Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$60,000
$6.49 P/Share
|
|
Oct 04
2021
|
Kenneth Carl Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
194
+0.23%
|
$8,536
$44.99 P/Share
|
|
Oct 04
2021
|
Alain J Cohen Director |
BUY
Grant, award, or other acquisition
|
Direct |
222
+50.0%
|
$9,768
$44.99 P/Share
|
|
Oct 04
2021
|
Marc A Cohen Director |
BUY
Grant, award, or other acquisition
|
Direct |
461
+50.0%
|
$20,284
$44.99 P/Share
|
|
Oct 04
2021
|
Glenn Dubin Director |
BUY
Grant, award, or other acquisition
|
Direct |
138
+31.87%
|
$6,072
$44.99 P/Share
|
|
Oct 04
2021
|
Malcolm Salter Director |
BUY
Grant, award, or other acquisition
|
Direct |
300
+2.22%
|
$13,200
$44.99 P/Share
|
|
Oct 01
2021
|
Adam Crystal Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,000
-57.65%
|
$675,000
$45.19 P/Share
|
|
Oct 01
2021
|
Adam Crystal Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$60,000
$4.98 P/Share
|